Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Merck is reportedly close to finalizing a deal to acquire Cidara Therapeutics, offering a premium over the biotechnology company’s current market value of about $3.3 billion. According to a report from the Financial Times, the agreement could be announced as early as Friday, assuming no last-minute complications arise. Sources familiar with the negotiations said Merck had been competing with another major pharmaceutical company up until late Thursday, but Cidara ultimately moved forward with Merck’s proposal.
Although the exact purchase price has not been disclosed, the deal is expected to consist of an upfront cash payment along with additional milestone-based payouts tied to future clinical achievements. Such structures are commonly used in the biotech sector, particularly when promising drug candidates are still in development.
Cidara Therapeutics declined to comment on the report, and Merck has not yet issued an official response. The potential acquisition comes at a pivotal moment for Cidara, which recently received breakthrough therapy designation from the U.S. Food and Drug Administration for its investigational drug CD388. The treatment is designed to prevent influenza A and B in individuals at high risk of severe illness, a population with significant unmet medical needs. The FDA’s breakthrough designation is intended to accelerate the development and review of innovative therapies that could offer substantial clinical benefits.
Industry analysts note that Merck’s interest in Cidara underscores its strategy to strengthen its infectious disease pipeline and expand its portfolio of next-generation antiviral treatments. If finalized, the acquisition would position Merck to capitalize on growing market demand for advanced flu prevention options, especially following heightened global awareness of respiratory viruses in recent years.
The reported deal highlights the increasing competition among pharmaceutical companies to secure cutting-edge biotech assets with strong clinical potential, reinforcing the value of innovative drug platforms in today’s healthcare landscape.
